OBJECTIVE: To determine whether changes in subcutaneous adipose tissue plasminogen activator inhibitor-1 (PAI-1) expression in¯uence plasma PAI-1 level during weight loss in obese humans. DESIGN: Study of the variations of PAI-1 levels both in plasma and in subcutaneous abdominal adipose tissue in 15 volunteer non-diabetic obese subjects, body mass index (BMI) 40.4. AE 1.9 kg/m 2 , aged 48 AE 3 y, before and after a 3 week very low calorie diet (VLCD) programme (3.9 AE 0.1 MJ/day). MEASUREMENTS: Plasma and adipose tissue PAI-1 protein levels were measured by enzyme-linked immunosorbent assay and PAI-1 mRNA levels were quanti®ed by quantitative RT-competitive PCR. RESULTS: VLCD induced weight loss (5.8 AE 0.8 kg) and decreased plasma PAI-1 concentration ( 7 26% (P`0.01)). Surprisingly, PAI-1 mRNA and protein abundance in subcutaneous adipose tissue increased by 87% (P`0.05) and by 44% (P`0.01), respectively. CONCLUSION: These data indicate thus that changes in subcutaneous adipose tissue PAI-1 expression are not involved in the decrease of plasma PAI-1 levels during VLCD in obese subjects.
Introduction
High levels of plasma plasminogen activator inhibitor-1 (PAI-1), the primary physiologic inhibitor of endogenous ®brinolysis, have been identi®ed as risk factor for cardiovascular disease (CVD). 1 However, the mechanisms underlying increased PAI-1 levels remain unknown. Hyperinsulinaemia is associated with high PAI-1 levels in obesity or in non-insulindependent diabetes mellitus, suggesting that PAI-1 could be a link between obesity, insulin resistance and CVD. 2 Accordingly, it was shown that weight loss due to diet, which improved insulin sensitivity, signi®cantly reduced plasma PAI-1 levels in obese subjects. 3 ± 5 In addition, it has been shown that PAI-1 can be produced by adipose tissue and suggested that this tissue could contribute to the plasma levels of PAI-1. 6 Moreover, a local increase in PAI-1 production by adipose cells has recently been proposed to be linked to the obese state both in rodents 7, 8 and in humans. 6, 9 Therefore, we hypothesized that the decrease of plasma PAI-1 concentration during diet-induced weight loss could be the result of a reduced PAI-1 expression in adipose tissue. To test this hypothesis, we have investigated the impact of a very low calorie diet (VLCD) programme on both the expression of the PAI-1 gene in subcutaneous abdominal adipose tissue and on the plasma PAI-1 levels in non-diabetic obese subjects.
Subjects and methods
Fifteen Caucasians (14 female, one male) obese (age 48 AE 3 y, body mass index (BMI) b 30.0 kg/ m 2 ) non-diabetic volunteers participated in the study. Apart from obesity, all subjects were in good health and had stable body weight for at least 12 months. They neither took any medication that could affect adipocyte metabolism nor were engaged in any type of exercise programme. None was excessively sedentary. We excluded patients with previous ischae-mic stroke, myocardial infarction, angina pectoris or who had an abnormal resting electrocardiogram. Careful assessment of chest pain was also undertaken to exclude all symptomatic patients. Finally, we excluded patients who had clinical liver disease, known hepatitis or who were heavy drinkers (alcohol intake b 20 g per day). During the VLCD programme, their daily energy intake was 3.9 AE 0.1 MJ (941 AE 27 kcal) with 45% of energy as carbohydrate, 20% as fat and 35% as protein. A subcutaneous abdominal adipose tissue biopsy was taken before and after a 3 week VLCD, after a 12 h fast, using the percutaneous mini-liposuction method described previously. 10 Brie¯y, following intradermal anaesthesia with 1% lidocaine, a vertical small slit was made in the abdominal skin of subjects and a liposuction mini-cannula (10 cmÂ3 mm) attached to a 20 ml sterile plastic syringe was inserted. Adipose tissue (1 ± 2 g) was drawn by successive suctions into the syringe. Adipose tissue samples were immediately frozen in liquid nitrogen and stored at 7 80 C until mRNA and protein analysis. All subjects had given their written consent after being informed of the nature, purpose and possible risks of the study. The experimental protocol was approved by the ethical committee of Assistance Publique, Ho Ãpitaux de Paris and performed according to the French legislation (Huriet law).
Analytical methods
Venous blood samples were taken from an antecubital vein in resting subjects around 8.00 a.m., after a 12 h fast, before and at the end of the diet period. Blood glucose, total cholesterol and triglycerides were assayed enzymatically using a multi-parametric analyser (Hitachi 911, Boehringer Mannheim, Meylan, France). Non-esteri®ed fatty acids (NEFA) were determined using a colorimetric method (NEFA C, Wako Gmbh, Neuss, Germany). Serum insulin (BiInsulin IRMA, ERIA-Pasteur, Paris, France) and leptin (Linco Research Inc., St Louis, MO, USA) concentrations were measured using commercial radioimmuno-assay kits. Determination of plasma PAI-1 antigen was performed by an enzyme linked immunosorbent assay with a commercially available kit (Asserachrom PAI-1 Stago, Asnie Áres, France) as previously described. 11 The same assays were used to determine both leptin and PAI-1 antigens in adipose tissue after homogenization of 200 mg of frozen tissue in 400 ml of a buffer (pH 7.4) containing 10 mmol/l of Tris ± HCl, 250 mmol/l of sucrose and a protease inhibitor cocktail (Complete TM , Boehringer Mannheim). Body composition was assessed by dual Xray absorptiometry (QDR 1000, Hologic, Watham, MA, USA), enabling quanti®cation of adipose tissue mass, lean body mass and total body bone mineral content. 12 Estimation of insulin resistance in the fasting state (fasting insulin resistance index, FIRI) was calculated from fasting plasma glucose and insulin levels (FIRI fasting glucoseÂfasting insulin/25), this index being closely correlated with insulin sensitivity assessed by clamp studies. 13 
RNA preparation
Total RNA from adipose tissue (about 200 mg of frozen tissue) was obtained using the RNeasy total RNA kit (Qiagen, Courtaboeuf, France). The absorption ratio 260 ± 280 nm was between 1.7 and 2.0 for all preparations. RNA integrity was veri®ed on agarose gel electrophoresis. Average yields were similar in samples obtained before (23 AE 2 mg of total RNA/g of tissue) and after diet (20AE 1 mg of total RNA/g of tissue).
Quanti®cation of target mRNAs
Human leptin and PAI-1 mRNAs were quanti®ed by reverse transcription-competitive polymerase chain reaction (RT-competitive PCR) which consisted in the co-ampli®cation of target cDNA with known amounts of a speci®c DNA competitor molecule added in the same PCR tube. 14 The reverse transcription reactions were performed from 0.1 mg of tissue total RNA in the presence of one of the speci®c antisense primers and 2.5 units of a thermostable reverse transcriptase (Tth, Promega, Charbonnie Áres, France). Fluorescent dye-labelled sense primers were used in the PCR, and the ampli®ed products were separated and analysed on a ALFexpress DNA sequencer (Pharmacia, Uppsala, Sweden) using the Fragment Manager software (Pharmacia). The conditions of the competitive PCR have been described in detail previously for leptin mRNA. 14 For the construction of the competitor DNA molecules for PAI-1, a 405 bp long cDNA fragment was obtained by RT-PCR on human adipose tissue total RNA using 5 H -1 ATGCAGATGTCTCCAGCCCT-CAC 23 -3 H (located in exon 2) as sense primer, 5
H -405 TGAATCTGGCTCTCTCCACCTC 384 -3 H (located in exon 3) as antisense primer, and high-®delity pfu DNA polymerase (Stratagen Inc., La Jolla, CA, USA), and subcloned using the pGEM-T Vector System (Promega). PAI-1 competitor DNA was obtained by deleting a 65 bp (from nucleotide 141 to 206) using a two-step PCR overlap extension method and pfu DNA polymerase. The identify of the two cDNA fragments (PAI-1 and competitor) to published human PAI-1 sequence 15 was veri®ed. To validate the assay, PAI-1 RNA was synthesized by in vitro transcription (Riboprobe System, Promega) and quanti®ed over a wide range of concentrations (from 0.75 to 50 amol of PAI-1 RNA added to the RT medium). The standard curve obtained (r 0.987, slope 1.3) demonstrated that the RT-competitive PCR assay of PAI-1 mRNA was quantitative. 14 PAI
Presentation of the results and statistical analysis
All results are presented as mean AE s.e. Target mRNA and protein values are presented as absolute concentrations, in amol/mg of tissue total RNA and ng/g adipose tissue, respectively. Non-parametric Wilcoxon's rank sum test for paired data was used to compare values before and after diet. The threshold for signi®cance was set at P 0.05. Table 1 summarizes the clinical and biological characteristics of the subjects before and after VLCD. All were characterized by android adipose tissue distribution (waist-to-hip ratio 0.99 AE 0.03). The low calorie diet resulted in $ 6 kg reduction in body weight, associated with an improvement of the insulin sensitivity ( Table 1 ). The weight loss was equally accounted for by reductions in adipose tissue mass and lean body mass. As shown in Table 1 , both fasting plasma triglycerides and total cholesterol decreased after VLCD, whereas NEFA increased, indicating increased lipolysis during the diet.
Results
PAI-1 antigen concentrations decreased by 26% (P`0.01) in the plasma after VLCD, whereas both PAI-1 mRNA and protein levels increased after VLCD in adipose tissue by 87% (0.23 AE 0.04 before vs 0.43 AE 0.11 amol/mg total RNA after VLCD, P0
.05) and 44% (10.4 AE 1.2 before vs 15.0 AE 1.6 ng/g adipose tissue after VLCD, P`0.01) respectively (Figure 1) .
In addition to PAI-1, we analysed the regulation of leptin expression during VLCD in both plasma and adipose tissue in 10 subjects. In these subjects, we observed a decrease in plasma leptin concentration (46 AE 3 before vs 35AE 4 ng/ml after VLCD, P`0.01) associated with a decrease in both leptin mRNA (199AE 27 before vs 115AE 22 amol/mg total RNA after VLCD, P`0.01) and leptin protein (13.8 AE 0.7 before vs 9.5 AE 0.6 ng/g adipose tissue after VLCD, P`0.01) in adipose tissue. We also measured b-actin mRNA levels in these adipose tissue samples. The expression of this housekeeping gene did not change during VLCD (210AE 27 before vs 231AE 28 amol/mg total RNA; P: NS).
We wondered whether the observed variations in plasma PAI-1 and both adipose PAI-1 mRNA and protein levels correlated with changes in various metabolic and hormonal parameters during VLCD.
The mean values of all the tested parameters are presented in Table 1 . The most striking result was a positive correlation between plasma PAI-1 and plasma triglycerides (r 0.699, P`0.01) before VLCD. After VLCD, the correlation between plasma PAI-1 levels and plasma triglycerides remained signi®cant (r 0.855, P`0.005). Plasma PAI-1 concentrations were also signi®cantly correlated with the BMI of the subjects before VLCD (0.575, P`0.05), but this correlation did not reach signi®cance (r 0.483, P 0.07) after the diet. No signi®cant correlation was found between the changes in the other measured metabolic and hormonal parameters and the modi®cations of plasma PAI-1 levels. In addition, there was no correlation between the mea- Figure 1 Effects of a very low calorie diet on PAI-1 mRNA and protein levels in subcutaneous adipose tissue of 15 obese subjects. *P`0.05; **P`0.01.
PAI-1 gene expression during very low calorie diet J-P Bastard et al sured metabolic and hormonal parameters and subcutaneous adipose tissue PAI-1 mRNA and protein content levels before and after VLCD. Finally, we did not ®nd any correlation between PAI-1 mRNA or protein contents in subcutaneous adipose tissue and plasma PAI-1 levels, both before and after VLCD.
Discussion
Circulating PAI-1 levels are elevated in obesity. Adipose tissue is a possible source of PAI-1 and may contribute to the increased plasma levels 16 in obese subjects. The present intervention study was designed to investigate the effects of VLCD on both plasma PAI-1 levels and adipose tissue PAI-1 gene expression in obese subjects. Our aim was to verify whether the changes in plasma PAI-1 levels during VLCD might result from a reduction in adipose tissue PAI-1 expression in vivo during a dynamic period of weight loss. In obese subjects, VLCD decreased plasma PAI-1, in agreement with previous reports.
± 5
Surprisingly, we found that both PAI-1 mRNA and protein concentrations increased in subcutaneous adipose tissue during VLCD, whereas the expression of leptin, another protein synthesized and secreted by human adipocytes, decreased both in plasma and in adipose tissue. These results demonstrate thus that the decrease in plasma PAI-1 observed during VLCD is not the result of a decrease in subcutaneous adipose tissue PAI-1 expression. However, one could not exclude that a possible decrease in the secretion rate of PAI-1 in adipose tissue participates in the lowering of plasma PAI-1. This hypothesis seemed unlikely since a close relationship between PAI-1 mRNA levels and PAI-1 secretion rate was reported in human adipose tissue explants. 9 Adipose tissue was obtained by mini-liposuction. 10 By using this method, we can obtain small pieces of adipose tissue that contain some capillaries, as in larger open adipose tissue biopsies. Therefore, the presence of endothelial cells may in¯uence the interpretation of the data. However, if the increase in adipose tissue PAI-1 expression after VLCD was related, in part, to the presence of capillaries, this did not explain the decrease in plasma PAI-1 levels.
It is now well accepted that visceral adipose tissue is the most important source of adipose-derived PAI-1. One could therefore not exclude the possibility that our results, obtained in subcutaneous abdominal adipose tissue, did not re¯ect all the adipose tissue deposits. For example, visceral adipose tissue PAI-1 expression might decrease during VLCD while increasing in subcutaneous adipose tissue. Although we did not have access to visceral fat in this study to verify this point, this hypothesis seemed unlikely since it has been clearly demonstrated that both PAI-1 synthesis and secretion were highly correlated in subcutaneous and in visceral adipose tissue explants from the same subjects. 17 Moreover, the same authors have stated that subcutaneous adipose tissue was thus a suitable model for studying the production of PAI-1 by adipose tissue. 17 Therefore, it is conceivable that our results re¯ect the regulation of PAI-1 expression in adipose tissue in humans.
Plasma PAI-1 levels were correlated with triglyceride concentrations both before and after VLCD. These results are in line with previous studies showing a positive relationship between lipid pro®le and ®brino-lysis in obesity-related insulin resistance. 2 They also suggest that plasma triglycerides could participate in the regulation of plasma PAI-1 levels, as already reported. 18 However, there was no correlation between PAI-1 expression in adipose tissue and plasma triglyceride levels, indicating that the mechanism of action of the triglycerides on PAI-1 levels may not involve the adipose tissue. On the other hand, despite the fact that no correlation was found between subcutaneous adipose PAI-1 expression and the different metabolic parameters tested either before or after VLCD, it is interesting to note that plasma NEFA concentration increased during VLCD, as did adipose tissue PAI-1 gene expression. Although the correlation between these parameters did not reach signi®cance, it cannot be excluded that NEFA may in¯uence the regulation of PAI-1 expression or secretion from adipose tissue or from other tissues, as previously suggested. 11 Further in vitro investigations are therefore needed to determine the regulatory mechanisms involved in the control of plasma PAI-1 levels and also PAI-1 gene expression in human adipose tissue.
Adipose tissue is known to express PAI-1 and leptin, and the synthesis of these proteins is upregulated in adipocytes from obese animals and humans. 16 Although changes in adipose tissue leptin expression are involved in the regulation of plasma leptin levels during diet in humans, our results demonstrate that the reduction in plasma PAI-1 levels do not result from a diet-induced decrease in subcutaneous adipose tissue PAI-1 expression. Therefore, the mechanisms that lead to the diminution in plasma PAI-1 levels are more complex and probably involved other cell types, such as endothelial cells or hepatocytes, rather than adipocytes. However, it should be noted that possible changes in the expression and/or secretion rate of PAI-1 in other adipose tissue deposits like visceral fat, which was recently proposed to be an important contributor of circulating PAI-1, 19 cannot be completely excluded from our study. Finally, it may be hypothesized that the clearance of circulating PAI-1 could be increased during the low calorie diet. Additional studies are thus required to elucidate the precise mechanisms involved in the regulation of plasma PAI-1 levels during dieting in human obesity.
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